← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Longeveron Inc. (LGVN) 10-Year Financial Performance & Capital Metrics

LGVN • • Industrial / General
HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring
AboutLongeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.Show more
  • Revenue $2M +237.4%
  • EBITDA -$16M +22.5%
  • Net Income -$16M +25.4%
  • EPS (Diluted) -1.07 +89.5%
  • Gross Margin 78.76% +152.7%
  • EBITDA Margin -650.67% +77.0%
  • Operating Margin -690.72% +76.7%
  • Net Margin -667.77% +77.9%
  • ROE -111.59% +29.0%
  • ROIC -312.33% -62.8%
  • Debt/Equity 0.07 -78.2%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Trading at only 0.4x book value

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Weak momentum: RS Rating 7 (bottom 7%)
  • ✗Sales declining 15.7% over 5 years
  • ✗Shares diluted 100.0% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-15.73%
3Y22.35%
TTM-22.41%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-19.1%

EPS CAGR

10Y-
5Y-
3Y-
TTM64.81%

ROCE

10Y Avg-78.83%
5Y Avg-86.65%
3Y Avg-100.17%
Latest-106.03%

Peer Comparison

Diagnostics & Immune Monitoring
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
TECHBio-Techne Corporation10.9B69.96152.095.23%6.41%3.97%2.35%0.23
SPRYARS Pharmaceuticals, Inc.1.1B11.09142.002970.63%-56.06%-54.21%1.18%0.00
VCYTVeracyte, Inc.3.24B41.00132.2623.46%6.12%2.41%1.97%0.04
CSBRChampions Oncology, Inc.99.56M7.1721.7313.54%4.32%59.65%7.03%1.62
MDXGMiMedx Group, Inc.851.59M5.7520.548.52%10.38%17.09%7.58%0.13
LTRNLantern Pharma Inc.39.26M3.51-0.00-197.36%0.01
SEERSeer, Inc.107.44M1.91-1.37-8.13%-486.02%-29.19%0.08
IMDXInsight Molecular Diagnostics Inc.189.76M6.62-1.4225.15%-13.81%-14.81%

Profit & Loss

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+2.13M5.63M5.63M1.31M1.22M709K2.39M
Revenue Growth %-1.64%-0%-0.77%-0.06%-0.42%2.37%
Cost of Goods Sold+1.45M3.8M3.8M716K725K488K508K
COGS % of Revenue0.68%0.68%0.68%0.55%0.59%0.69%0.21%
Gross Profit+680.65K1.83M1.83M590K497K221K1.88M
Gross Margin %0.32%0.32%0.32%0.45%0.41%0.31%0.79%
Gross Profit Growth %-1.68%-0%-0.68%-0.16%-0.56%7.52%
Operating Expenses+7.04M5.6M5.6M18.05M18.54M21.25M18.41M
OpEx % of Revenue3.3%1%1%13.82%15.17%29.97%7.69%
Selling, General & Admin3.17M2.93M2.93M10.95M9.17M12.18M10.27M
SG&A % of Revenue1.48%0.52%0.52%8.39%7.5%17.18%4.29%
Research & Development3.88M2.67M2.67M7.09M9.37M9.07M8.14M
R&D % of Revenue1.82%0.48%0.48%5.43%7.67%12.79%3.4%
Other Operating Expenses0000000
Operating Income+-6.36M-3.78M-3.78M-17.46M-18.04M-21.03M-16.52M
Operating Margin %-2.98%-0.67%-0.67%-13.37%-14.77%-29.66%-6.91%
Operating Income Growth %-0.41%0%-3.62%-0.03%-0.17%0.21%
EBITDA+-5.61M-3.01M-2.99M-16.54M-17.15M-20.08M-15.56M
EBITDA Margin %-2.63%-0.53%-0.53%-12.67%-14.03%-28.33%-6.51%
EBITDA Growth %-0.46%0.01%-4.53%-0.04%-0.17%0.23%
D&A (Non-Cash Add-back)745.77K768.84K785K914K893K946K958K
EBIT-6.34M-3.71M-3.71M-17.04M-18.04M-21.03M-16.52M
Net Interest Income+23.82K2.77K-6.4K-4K000
Interest Income23.82K2.94K1390000
Interest Expense01696.54K4K000
Other Income/Expense23.82K57.47K57K411K-792K-384K549K
Pretax Income+-6.34M-3.72M-3.72M-17.05M-18.84M-21.41M-15.97M
Pretax Margin %-2.97%-0.66%-0.66%-13.05%-15.41%-30.2%-6.68%
Income Tax+23.82K000000
Effective Tax Rate %1%1%1%1%1%1%1%
Net Income+-6.34M-3.72M-3.72M-17.05M-18.84M-21.41M-15.97M
Net Margin %-2.97%-0.66%-0.66%-13.05%-15.41%-30.2%-6.68%
Net Income Growth %-0.41%-0%-3.58%-0.11%-0.14%0.25%
Net Income (Continuing)-6.34M-3.72M-3.72M-17.05M-18.84M-21.41M-15.97M
Discontinued Operations0000000
Minority Interest0000000
EPS (Diluted)+-3.98-1.87-2.21-9.00-9.00-10.22-1.07
EPS Growth %-0.53%-0.18%-3.07%0%-0.14%0.9%
EPS (Basic)-3.98-1.87-2.21-9.00-9.00-10.22-1.07
Diluted Shares Outstanding1.59M1.6M1.69M1.89M2.1M2.17M14.89M
Basic Shares Outstanding1.59M1.6M1.69M1.89M2.1M2.17M14.89M
Dividend Payout Ratio-------

Balance Sheet

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+4.16M2.37M1.85M35.38M20.28M5.85M19.62M
Cash & Short-Term Investments4.03M1.87M816K35.04M19.66M5.36M19.23M
Cash Only4.03M1.87M816K25.66M10.5M4.95M19.23M
Short-Term Investments0009.38M9.15M412K0
Accounts Receivable0451.46K420K55K218K111K84K
Days Sales Outstanding-29.2727.2315.3765.1157.1412.82
Inventory0000000
Days Inventory Outstanding-------
Other Current Assets00561K0404K376K308K
Total Non-Current Assets+6.36M8.21M7.39M7.39M7.13M6.23M5.93M
Property, Plant & Equipment4.76M6.48M5.67M4.88M4.48M3.75M3.33M
Fixed Asset Turnover0.45x0.87x0.99x0.27x0.27x0.19x0.72x
Goodwill0000000
Intangible Assets1.35M1.48M1.55M2.33M2.41M2.29M2.4M
Long-Term Investments0000000
Other Non-Current Assets250.89K250.89K177K177K244K193K202K
Total Assets+10.52M10.58M9.24M42.77M27.41M12.08M25.56M
Asset Turnover0.20x0.53x0.61x0.03x0.04x0.06x0.09x
Asset Growth %-0.01%-0.13%3.63%-0.36%-0.56%1.12%
Total Current Liabilities+1.86M2.49M3.83M2.71M4.87M3.89M2.58M
Accounts Payable1.21M1.15M1.59M645K1.75M638K99K
Days Payables Outstanding302.57110.82152.6328.81881.54477.1971.13
Short-Term Debt00177K0000
Deferred Revenue (Current)405K541.79K10K199K506K506K40K
Other Current Liabilities209.26K0001.4M00
Current Ratio2.24x0.95x0.48x13.06x4.17x1.50x7.60x
Quick Ratio2.24x0.95x0.48x13.06x4.17x1.50x7.60x
Cash Conversion Cycle-------
Total Non-Current Liabilities+1.84M3.65M3.45M2.6M2.04M1.45M1.09M
Long-Term Debt00311K0000
Capital Lease Obligations03.65M3.14M2.6M2.04M1.45M824K
Deferred Tax Liabilities0000000
Other Non-Current Liabilities1.84M00000265K
Total Liabilities3.71M6.14M7.28M5.31M6.91M5.34M3.67M
Total Debt+04.14M4.14M3.14M2.6M2.04M1.45M
Net Debt-4.03M2.27M3.33M-22.52M-7.9M-2.91M-17.79M
Debt / Equity-0.93x2.12x0.08x0.13x0.30x0.07x
Debt / EBITDA-------
Net Debt / EBITDA-------
Interest Coverage--22356.67x-577.59x-4364.00x---
Total Equity+6.81M4.45M1.96M37.45M20.5M6.74M21.89M
Equity Growth %--0.35%-0.56%18.14%-0.45%-0.67%2.25%
Book Value per Share4.282.781.1619.809.783.101.47
Total Shareholders' Equity6.81M4.45M1.96M37.45M20.5M6.74M21.89M
Common Stock7.11M01.96M21K21K2K14K
Retained Earnings000-43.94M-62.77M-84.98M-109.61M
Treasury Stock0000000
Accumulated OCI-1.39M000-357K00
Minority Interest0000000

Cash Flow

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-5.18M-2.39M-2.36M-9.64M-13.97M-19M-13.87M
Operating CF Margin %-2.43%-0.42%-0.42%-7.38%-11.43%-26.8%-5.8%
Operating CF Growth %-0.54%0.01%-3.08%-0.45%-0.36%0.27%
Net Income-6.34M-2.96M-3.72M-17.05M-18.84M-21.41M-15.97M
Depreciation & Amortization745.77K768.84K785.44K914K893K946K958K
Stock-Based Compensation423.87K136.85K83K7.74M2.17M2.03M2.33M
Deferred Taxes0000000
Other Non-Cash Items1.9M-120.13K-167-155K1.57M-603K60K
Working Capital Changes-11.22K-216.48K488.63K-1.09M238K36K-1.24M
Change in Receivables24.88K-451.46K30.81K366K-164K107K27K
Change in Inventory00-30.81K-366K000
Change in Payables-13.09K0130.94K-945K1.11M0-540K
Cash from Investing+-211.68K-125.05K-261.5K-10.7M-677K8.19M-640K
Capital Expenditures-211.68K-37.57K-261.5K-1.31M-856K-301K-992K
CapEx % of Revenue0.1%0.01%0.05%1%0.7%0.42%0.41%
Acquisitions-------
Investments-------
Other Investing-115.72K-87.47K0-9.39M08.49M0
Cash from Financing+1.35M350K1.58M45.17M-509K5.26M28.79M
Debt Issued (Net)-------
Equity Issued (Net)-------
Dividends Paid000000-8.65M
Share Repurchases-------
Other Financing1.35M350K-12.67K-451K-511K5.44M24.57M
Net Change in Cash-------
Free Cash Flow+-5.39M-2.43M-2.63M-10.95M-14.82M-19.3M-14.86M
FCF Margin %-2.52%-0.43%-0.47%-8.38%-12.13%-27.23%-6.21%
FCF Growth %-0.55%-0.08%-3.17%-0.35%-0.3%0.23%
FCF per Share-3.39-1.52-1.56-5.79-7.07-8.88-1.00
FCF Conversion (FCF/Net Income)0.82x0.64x0.64x0.57x0.74x0.89x0.87x
Interest Paid0000000
Taxes Paid0000000

Key Ratios

Metric2018201920202021202220232024
Return on Equity (ROE)-92.99%-66.09%-116.24%-86.5%-65%-157.19%-111.59%
Return on Invested Capital (ROIC)-171.44%-59.66%-47.23%-129.5%-98.27%-191.89%-312.33%
Gross Margin31.88%32.44%32.44%45.18%40.67%31.17%78.76%
Net Margin-296.84%-66.09%-66.1%-1305.13%-1541.33%-3020.17%-667.77%
Debt / Equity-0.93x2.12x0.08x0.13x0.30x0.07x
Interest Coverage--22356.67x-577.59x-4364.00x---
FCF Conversion0.82x0.64x0.64x0.57x0.74x0.89x0.87x
Revenue Growth-163.71%-0.01%-76.8%-6.43%-41.98%237.38%

Frequently Asked Questions

Growth & Financials

Longeveron Inc. (LGVN) reported $1.4M in revenue for fiscal year 2024. This represents a 33% decrease from $2.1M in 2018.

Longeveron Inc. (LGVN) grew revenue by 237.4% over the past year. This is strong growth.

Longeveron Inc. (LGVN) reported a net loss of $21.3M for fiscal year 2024.

Dividend & Returns

Yes, Longeveron Inc. (LGVN) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.

Longeveron Inc. (LGVN) has a return on equity (ROE) of -111.6%. Negative ROE indicates the company is unprofitable.

Longeveron Inc. (LGVN) had negative free cash flow of $17.0M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.